UBE2N

Ubiquitin-conjugating enzyme E2 N · P61088 · UBE2N on Sugi Atlas →

39,801 patent compounds predicted against UBE2N, 27,116 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL168402	0.42	4/20
Safingol (SCHEMBL6772)	1.00	3/20
Dihydrospingosine (SCHEMBL40591)	1.00	3/20
Dihydrospingosine (SCHEMBL40592)	1.00	3/20
Safingol (SCHEMBL7651)	0.96	3/20
Phytosphingosine (SCHEMBL20110)	0.78	3/20
SCHEMBL360356	0.70	3/20
SCHEMBL191662	0.59	3/20
SCHEMBL314278	0.53	3/20
SCHEMBL304332	0.44	3/20
Sphingosine (SCHEMBL19398)	1.00	2/20
Sphingosine (SCHEMBL19399)	1.00	2/20
Fluphenazine (SCHEMBL41634)	1.00	2/20
Fluphenazine (SCHEMBL41635)	1.00	2/20
Perphenazine (SCHEMBL42125)	1.00	2/20
Perphenazine (SCHEMBL140891)	0.98	2/20
Perphenazine (SCHEMBL145754)	0.98	2/20
Sphingosine (SCHEMBL195874)	0.97	2/20
Sphingosine (SCHEMBL195875)	0.97	2/20
Sphingosine (SCHEMBL19137)	0.85	2/20

Clinical trials — most relevant to UBE2N by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis	PHASE2/PHASE3	UNKNOWN
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy	nan	COMPLETED
A Natural History Study of Angelman Syndrome	nan	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Endocrine Disruptors and Life STILe in Breast Cancer Development	nan	UNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk	nan	NOT_YET_RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome	nan	RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a UBE2N binder may also engage these)

Protein	Name	Similarity
Q5R7J6	—	1.000	Q5R7J6 →
P61089	—	1.000	P61089 →
Q95XX0	—	1.000	Q95XX0 →
Q0P5K3	—	1.000	Q0P5K3 →
Q9EQX9	—	1.000	Q9EQX9 →
Q4R4I1	—	1.000	Q4R4I1 →
P35128	—	1.000	P35128 →
Q86K32	—	1.000	Q86K32 →
P25866	—	0.998	P25866 →
Q5JXB2	—	0.997	Q5JXB2 →
P61087	—	0.997	P61087 →
Q94A97	—	0.997	Q94A97 →
P25153	—	0.996	P25153 →
P42746	—	0.996	P42746 →
Q96UP5	—	0.996	Q96UP5 →
Q9FZ48	—	0.996	Q9FZ48 →
Q9UTN8	—	0.996	Q9UTN8 →
Q2EF73	—	0.995	Q2EF73 →
Q28CQ4	—	0.995	Q28CQ4 →
Q9Z255	—	0.995	Q9Z255 →
P52490	—	0.995	P52490 →
P63280	—	0.995	P63280 →
P63283	—	0.995	P63283 →
P63281	—	0.995	P63281 →
O13685	—	0.995	O13685 →
P35130	—	0.995	P35130 →
Q4WLA7	—	0.995	Q4WLA7 →
P52486	—	0.995	P52486 →
P62253	—	0.994	P62253 →
Q6Y1Z4	—	0.994	Q6Y1Z4 →